Literature DB >> 27974407

State-of-the-Art Review of Echocardiographic Imaging in the Evaluation and Treatment of Functional Tricuspid Regurgitation.

Rebecca T Hahn1.   

Abstract

Functional or secondary tricuspid regurgitation (TR) is the most common cause of severe TR in the Western world. The presence of functional TR, either isolated or in combination with left heart disease, is associated with unfavorable natural history. Surgical mortality for isolated tricuspid valve interventions remains higher than for any other single valve surgery, and surgical options for repair do not have consistent long-term durability. In addition, as more patients undergo transcatheter left valve interventions, developing transcatheter solutions for functional TR has gained greater momentum. Numerous transcatheter devices are currently in early clinical trials. All patients require an assessment of valve morphology and function, and transcatheter devices typically require intraprocedural guidance by echocardiography. The following review will describe tricuspid anatomy, define echocardiographic views for evaluating tricuspid valve morphology and function, and discuss imaging requirements for the current transcatheter devices under development for the treatment of functional TR.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  echocardiography; three-dimensional echocardiography; transcatheter; transesophageal echocardiography; transthoracic echocardiography; tricuspid valve; tricuspid valve insufficiency

Mesh:

Year:  2016        PMID: 27974407     DOI: 10.1161/CIRCIMAGING.116.005332

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  29 in total

1.  Transcatheter pledget-assisted suture tricuspid annuloplasty (PASTA) to create a double-orifice valve.

Authors:  Jaffar M Khan; Toby Rogers; William H Schenke; Adam B Greenbaum; Vasilis C Babaliaros; Gaetano Paone; Rajiv Ramasawmy; Marcus Y Chen; Daniel A Herzka; Robert J Lederman
Journal:  Catheter Cardiovasc Interv       Date:  2018-02-06       Impact factor: 2.692

Review 2.  An update on intraoperative three-dimensional transesophageal echocardiography.

Authors:  Lisa Qia Rong
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

Review 3.  Multi-Modality Imaging in the Evaluation and Treatment of Tricuspid Regurgitation.

Authors:  Samuel M Kim; Harsimran S Singh; Jillian Nati; Jonathan N Ginns
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-08-09

4.  Functional tricuspid regurgitation: indications, techniques, and outcomes.

Authors:  Tessa M F Watt; Alexander A Brescia; Aaron M Williams; Steven F Bolling
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2020-01-09

5.  Current transcatheter devices to treat functional tricuspid regurgitation with discussion of issues relevant to clinical trial design.

Authors:  Rebecca T Hahn
Journal:  Ann Cardiothorac Surg       Date:  2017-05

6.  Transcatheter Treatment of Functional Tricuspid Regurgitation Using the Trialign Device.

Authors:  Christian Besler; Christopher U Meduri; Philipp Lurz
Journal:  Interv Cardiol       Date:  2018-01

Review 7.  [MitraClip® for treatment of tricuspid valve insufficiency].

Authors:  R Pfister; S Baldus
Journal:  Herz       Date:  2017-11       Impact factor: 1.443

Review 8.  Role of Echocardiography in Transcatheter Valvular Heart Disease Interventions.

Authors:  Omar K Khalique; Rebecca T Hahn
Journal:  Curr Cardiol Rep       Date:  2017-10-27       Impact factor: 2.931

Review 9.  Tricuspid valve disease: diagnosis, prognosis and management of a rapidly evolving field.

Authors:  Lluis Asmarats; Maurizio Taramasso; Josep Rodés-Cabau
Journal:  Nat Rev Cardiol       Date:  2019-09       Impact factor: 32.419

10.  Clinical performance and exercise hemodynamics in patients with severe secondary tricuspid regurgitation and chronic atrial fibrillation.

Authors:  Jesper K Jensen; Tor S Clemmensen; Christian A Frederiksen; Joachim Schofer; Mads J Andersen; Steen H Poulsen
Journal:  BMC Cardiovasc Disord       Date:  2021-06-04       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.